Pharvaris, a clinical-stage company specializing in the development of innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, recently made an exciting announcement. The organization revealed that it has been invited to present at the GALEN UCARE Conference 2023, a prestigious event to be held from December 7-9, 2023, at the Rebouas Convention Center in São Paulo, Brazil.
During this conference, Pharvaris has been granted the opportunity to deliver one oral presentation and showcase two poster presentations. The abstracts submitted by the company were accepted, highlighting the significant impact and value of Pharvaris’ research and contributions to the field of HAE treatment.
This recognition at such a prominent conference underscores Pharvaris’ dedication to advancing the understanding of hereditary angioedema and finding effective solutions for patients. The company’s commitment to developing oral bradykinin B2 receptor antagonists showcases its innovative approach to addressing this debilitating condition, offering hope to HAE sufferers worldwide.
The GALEN UCARE Conference is a renowned platform that brings together industry experts, researchers, healthcare professionals, and stakeholders from around the globe. By participating in this event, Pharvaris gains valuable exposure and networking opportunities, allowing it to enhance its reputation and forge potential collaborations with other key players in the field.
The acceptance of abstracts for both oral and poster presentations further signifies Pharvaris’ advancements in the field of HAE research. These presentations will provide the company with a unique platform to share its findings, engage in scientific discussions, and gather crucial insights from other leading experts. Such interactions can potentially contribute to the growth and development of Pharvaris’ research and future innovations.
All in all, Pharvaris’ acceptance of abstracts for the GALEN UCARE Conference 2023 highlights the recognition and impact the company has in the field of HAE treatment. This opportunity solidifies Pharvaris’ dedication to transforming the lives of HAE patients through its pioneering oral bradykinin B2 receptor antagonists.
Comments